Table 2 Evidence-based studies since 2014.
Study (Season) | Study description | Age group | Key outcomes |
|---|---|---|---|
Multicenter, noninterventional, observational cohort | 29–35 wGA <12 months CA | • RSVH was severe and often required ICU admission and IMV in most preterm infants who did not receive IP • Infants of earlier GA and younger CA were associated with higher disease severity (ICU admission and need for IMV) and hospital charges | |
Kong et al. (2013–2014 vs 2014–2015) [38] | Truven Commercial and Medicaid databases | 29–34 wGA <6 months CA | • RSV IP use decreased significantly • Rate ratio of RSVH in preterm infants vs term infants increased |
Goldstein et al. (2012–2014 vs 2014–2016) [39] | Truven Commercial and Medicaid databases | 29–34 wGA <6 months CA | • RSV IP use decreased significantly • Rate ratio of RSVH in preterm infants vs term infants increased |
Rajah et al. (2013–2014 vs 2014–2015) [47] | Single-center, retrospective study | 29–34 wGA <12 months CA | • RSVH, severity, and hospital charges significantly increased in preterm infants born at 29–34 wGA |
Blake et al. (2012–2014 vs 2014–2016) [48] | Single-center, retrospective cohort | 29–32 wGA <12 months CA | • RSV IP use decreased significantly • RSVH increased significantly in preterm infants born at 29–32 wGA |
Farber et al. (2012–2014 vs 2014–2015) [40] | Retrospective study from Texas | 29–32 wGA <6 months CA | • No significant change in RSVH |
Grindeland et al. (2012–2014 vs 2014–2015) [42] | Single-center, retrospective study | <2 years CA | • RSV IP use decreased significantly • No significant change in RSVH |
Zembles et al. (2012–2014 vs 2014–2017) [46] | Single-center, retrospective study | 29–35 wGA <12 months CA | • No significant change in RSVH or morbidity except for duration of hospitalization |
